|Bid||0.0220 x 0|
|Ask||0.0240 x 0|
|Day's range||0.0220 - 0.0250|
|52-week range||0.0150 - 0.0620|
|Beta (5Y monthly)||1.52|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||0.11|
In addition to this, through the MGC sales and distribution agreement, Allied will be able to sell their products following the completion of the PHASE I clinical trial. MGC currently has cannabis-based pharmaceutical products for sale in Europe and has demonstrated a proven ability to commercialize cannabis based pharmaceutical products.
Every investor in MGC Pharmaceuticals Limited (ASX:MXC) should be aware of the most powerful shareholder groups...